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Summary  
This article presents an analysis of challenges and considerations when 
developing digital mental health innovations.  Recommendations include 
collaborative working between clinicians, researchers, industry and service 
users in order to successfully navigate challenges and to ensure e-therapies 
are engaging, acceptable, evidence-based, scalable and sustainable.   
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Introduction 
Digital mental health innovation has seen rapid growth in the last few years, 
with an increasing range of psychological interventions available online and 
via smartphone or tablet application (apps).  Technology has progressed from 
computerised cognitive behavioural therapy (cCBT) (e.g. "Beating the Blues" 
1), to mood rater apps (e.g. 2) and digital interventions that are fully integrated 
within services (e.g. 3), with wearable technology (e.g. 4) on the horizon.   
The appetite for these “e-therapies” is driven by a multitude of factors, 
including the extraordinary rate in which society is adopting technology into 
their everyday lives (5), the pressures on healthcare providers to deliver more 
for less money, a drive for services to be delivered flexibly in a patient-centred 
manner and the empowerment that e-therapies can bring to service users by 
enabling them to make choices about when and how they access 
psychological care (6). 
 
Australia and the US have been leaders in this field, perhaps unsurprisingly 
given the need to provide accessible services for their rural and remote 
communities.  However, several government initiatives within the UK have set 
out to promote digital mental health, including ‘No Health without Mental 
Health’ (7) and ‘Digital First’ (8) . Now that the UK has woken up to the 
possibilities that the technological revolution brings within healthcare, there is 
an exciting opportunity to learn from the lessons learnt internationally and take 
a lead in developing, evaluating and disseminating e-therapies.  This is 
particularly salient for the UK, and many other countries worldwide, as the 
demand for psychological services goes beyond what is currently provided. 
As such there is a clear need for mental health services within the National 
Health Service (NHS) to consider innovative ways to deliver services on a 
limited budget.  Online evidence-based psychological treatments can help 
improve clinical efficiency, are cost-effective and can ultimately increase 
access to treatment.     
 
Whilst UK clinical and research communities have been slow at digital mental 
health innovation, industry has been quick to spot a lucrative and 
commercially appealing opportunity.  Various industry-produced e-therapies 
have been commissioned across the UK’s National Health Service (NHS) and 
apps have been listed on the NHS choices website (although are not 
currently), despite a lack of scientific evidence underpinning these (9).  Whilst 
plans are underway to employ an accreditation system for health apps in the 
UK, led by the National Information Board (10), it is unclear whether this will 
reflect the standards typically adhered to for the recommendation of 
psychological treatments e.g. by the UK’s National Institute for Health and 
Care Excellence (NICE).  
 
One of the challenges faced by clinical and research communities is how to 
maintain sufficient control of the digital mental health revolution to ensure that 
e-therapies have an appropriate evidence base.  This is complicated by the 
need to balance scientific rigour with the fast pace that technology advances 
and ultimately to achieve the adoption of evidence-based e-therapies by the 
NHS and other healthcare providers.  Although the evidence base for e-
therapies is growing, with sufficient publications to permit various systematic 
reviews (e.g. 11, 12, 13) and a dedicated journal (Internet Interventions), the 
number of available e-therapies far outstrips the number of evaluations. 
 
Through our experience of digital mental health innovation we have all been 
struck by the lack of guidance and formalised approaches to development 
within e-health.  As such, this analysis aims to open a discussion about how 
academics and clinicians can best develop, evaluate and disseminate e-
therapies. Whilst our focus is on navigating these challenges within the UK, 
the principles apply more broadly and it is hoped that this article will contribute 
to a framework for how digital mental health innovation can be approached 
internationally.   
 
Development options 
Industry leading development 
In the UK, commercial organisations have primarily taken a lead on the 
development of digital mental health innovations and have produced most of 
the e-therapies and apps that are available.  Examples that are available in 
the UK include the Big White Wall, IESO Digital Health (14), Kooth, and Mood 
District.  Commercial organisations, with expertise in online or app-based 
technology, may have an advantage over healthcare and academic 
organisations in terms of their skills and experience in both producing and 
commercialising usable and engaging products. However, they may lack 
knowledge on the care pathway or the clinical, patient and healthcare system 
benefits that are required to develop cost and clinically effective products. 
Furthermore, industry may not be best placed to involve service users and 
healthcare professionals in the co-design of digital products. These 
considerations highlight the need for effective joint working between 
healthcare providers and industrial partners. 
 
Some local NHS organisations have commissioned commercially developed 
e-therapies (e.g. Big White Wall and Kooth), however these technologies 
have not yet been widely adopted across the NHS.  A possible reason for this 
is that these products are reaching the market prior to any formal evaluation 
of their efficacy and without high quality peer-reviewed research evidence.  An 
exception to this is “Beating the Blues” which is NICE approved (15), although 
this has recently been found to offer no additional benefit beyond usual GP 
care (16).  As many e-therapies are based on Cognitive Behaviour Therapy 
(CBT), there can be a tendency for developers to claim that they are 
evidence-based as CBT itself may have an evidence base with a particular 
patient population. Yet clearly the evidence-informed novel e-therapy is not 
the same as the non-e-therapy version, and may differ in relation to service 
user engagement, acceptability, therapeutic alliance, processes of change 
and ultimately treatment outcomes (17).  While some industrial providers have 
established academic partnerships to evaluate their products once they have 
been disseminated, evaluating online treatments retrospectively sits at odds 
with the principle of evidence-based practice and raises difficulties if the 
research does not produce favourable results.  We recommend involving 
academic partners from the start to ensure that adequate and appropriate 
evaluation is built into the development plan.  
 
 In-house development within the NHS 
Those working within the NHS may have the option of using in-house 
expertise from their Trust’s internal website development team.  In-house 
options may seem appealing, as they are likely to appear more affordable 
than commissioning external organisations.  However, this should be 
balanced with the extensive time required from internal personnel, the need 
for specific skills and resources, and the fit with the organisation’s broader 
strategic vision.  Examples of NHS built innovations that have now been rolled 
out into clinical services include a moderated social network for service users, 
first developed for adults with eating disorders (the Support Hope and 
Recovery Online Network,SHaRON) created in Berkshire Healthcare 
Foundation Trust, and a SMS texting helpline for school nurses to support 
young people (ChatHealth) which was set by up Leicestershire Partnership 
NHS Trust. 
 
As for industry-led developments, rigorous evaluation has not always been 
central to the development of e-therapies within the NHS, presumably 
reflecting a lack of time or available resources to undertake research beyond 
routine service audit.  Notably in the most recent reviews of digital 
interventions for anxiety and depression (13, 18) there were no examples of 
clinical or health-economic outcomes associated with e-therapies that have 
been developed within the NHS.   Some NHS-led digital innovations for 
bipolar disorder and psychosis have promising research behind them (e.g. 19, 
20) but have yet to be adopted at scale across the NHS (21).   
 Individual NHS Trusts that develop e-therapies will also need to consider 
whether and how to disseminate innovations beyond their Trust.  
Disseminating the innovation to other Trusts (and healthcare systems) 
maximises its reach and may provide an income stream for the Trust that led 
the development. Although there may be initial resistance to commission the 
innovation from other NHS Trusts due to a desire to create their own 
innovations, the growing recognition of the specialist skills and time required 
to develop and evaluate e-therapies is likely to promote between-Trust 
commissioning going forwards.  Effective communication regarding what is 
already available will be critical going forwards to prevent NHS Trusts 
reinventing the ‘digital wheel’, and to enhance learning from both successful 
and unsuccessful case studies in the NHS.   
 
In-house development within universities 
The work of Gerhard Andersson and colleagues in Sweden is arguably the 
most prolific example of e-therapy development within a university setting.  
This group have established their own in-house web developer to create 
psychological interventions (22) which has enabled the rapid and cost-
effective development and evaluation of a range of online interventions with 
demonstrated efficacy compared to a waitlist control (23) and equivalence to 
face-to-face treatment (e.g. 24, 25).   
 
An alternative approach that university-based researchers have commonly 
taken is to use external funding to commission a private company to build, 
host and maintain a website and/or app.  Most of the online treatment 
programmes for child and adolescent anxiety have taken this approach 
(e.g.26, 27, 28).  A particular consideration here is that research funding is 
often fairly slow moving, with lags between bids and awards often being over 
12 months. Furthermore, if a tendering procedure is required, this again can 
be slow, with a UK tender typically taking 6 months and EU up to 9 months.  
In contrast digital innovation moves at a fast pace, and what may have been 
‘innovative’ at the time the idea was conceived, may become technologically 
redundant by the time the project starts and technical specifications may need 
to change.  Academics will also need to keep in mind that research funding 
may cover development, maintenance and hosting of the website/app for a 
specified period (typically the grant duration) but it is unlikely to cover the 
costs of maintaining and hosting the online tool beyond this period. Equally 
initial funds are unlikely to cover the cost of changes that may be needed to 
the content or technical specifications, in response to research and 
development and changes in devices and operating systems. All of these 
funding limitations create the risk that the e-therapy may become out of date 
without additional sources of funding being secured. As such, it is important 
that developers consider scalability and sustainability from the outset of any 
digital mental health project, including consideration of how the e-therapy will 
be disseminated within NHS Trusts.  One approach is to work in partnership 
with an external company who supply digital mental healthcare solutions and 
who could take the product to market.  This could ultimately result in a 
revenue stream to maintain and upgrade the system. 
 
Working collaboratively with industry     
An alternative approach to digital mental health innovation that has the 
potential to overcome many of the challenges highlighted above is for 
clinicians and researchers to work in a collaborative partnership with a 
website/app development company. Here clinical and academic partners can 
contribute clinical insight and research skills whilst the industrial partner brings 
technical knowledge, and experience of working in the digital health space 
and of getting products adopted by the NHS.  An example is an online CBT 
platform that is used routinely across several Improving Access to 
Psychological therapies (IAPT) services which was developed collaboratively 
by Berkshire NHS Foundation Trust, who provided the treatment content, and 
Silvercloud Health, who developed the technology and market the product to 
other healthcare providers.  Academic partnerships have facilitated research 
into the efficacy and acceptability of the platform (29, 30).    
 
Collaborations between clinical, academic, and industrial partners facilitate 
the development of innovations that are based on sound psychological theory 
and clinical practice that has a demonstrable evidence-base and that has 
research and evaluation firmly built in to the development phase (i.e. prior to 
commercialisation).  Through a collaborative arrangement all parties are likely 
to be invested in making a product that is sustainable and scalable.  Another 
advantage of the collaborative approach for industrial partners is that it 
facilitates access to the views of potential beneficiaries of the product (e.g. 
service users) to inform development and to contribute to design and usability 
testing.  Incorporating the views of potential beneficiaries throughout the 
development process is likely to ultimately lead to the development of a 
product that is engaging, credible, relevant and valued within services.    
 
Pitfalls of the collaborative approach include potential changes in the direction 
of the company’s business plan which may then deviate from shared goals, or 
that the company’s financial situation may not allow them to continue to 
support the collaboration e.g. if they fold or are taken over.  Another potential 
issue is that aims of the groups may differ, with the commercial partner likely 
motivated to take the product in a direction that results in greater financial 
rewards, whilst the clinical/academic partners may be more concerned with 
channelling resources into adapting the innovation to maximise effectiveness.  
Appropriate steps need to be taken when contractual terms are agreed to 
mitigate these risks.  
 
Development considerations 
Across all development options, co-design between clinicians, researchers, 
industry and service users is crucial.  Applying principles from the human 
factors approach to co-design would help ensure the tool is relevant, usable 
and engages users (31).  Careful consideration should be given to specific 
populations such as older adults whose ability to work with digital technology 
is variable, or forensic patients in secure settings who may have restricted 
access to information technology.  There is also an issue about how to best 
manage and appropriately analyse the enormity of data (“big data”) generated 
using digital tools, alongside connectivity complexities e.g. ensuring digital 
tools can integrate into healthcare systems and retain internet connection in 
different health settings.     
 
Multiagency working 
Careful consideration should be given to intellectual property (IP) when 
planning the development of a novel e-therapy. This will be relatively straight-
forward when developing a digital solution in-house within NHS or academic 
settings, as the IP will be owned exclusively by that organisation. This will also 
typically be the case when an external website development company are 
commissioned to develop a bespoke product.  However, there may be limited 
commercial appeal for industry to work collaboratively in partnership with 
clinicians/researchers to develop bespoke technologies, if they are unable to 
use this technology in other ventures.  Careful identification and assignment 
of potential IP and the terms under which it will be licensed to the other 
party/parties is crucial at the outset of any collaboration, and will usually 
require specialised internal or external legal support. 
 
In the UK, a number of organisations have been set up to encourage the 
development and evaluation of healthcare innovations such as the NHS 
England-funded Academic Health Science Networks (AHSNs) and NIHR 
MindTech Healthcare Technology Co-operatives (HTC). AHSNs work with a 
wide group of collaborators, from industry, academia and the NHS to speed 
up the adoption of proven products and services into the NHS. They also 
support innovations through the development pathway to ensure that they 
meet the needs of the NHS and its patients.   
 Commercialisation 
Whichever route is followed to develop and evaluate a novel e-therapy, 
specific attention should be given to how the product can be disseminated in a 
way that will generate funds to cover ongoing maintenance, research and 
development.  In the UK, adoption by the NHS is typically the Holy Grail for 
digital mental health innovation.  A clear business model is crucial to achieve 
this and will need to include consideration of the potential market, what the 
problem is that needs to be solved in any given care pathway, how the 
technology or product provides a solution to this problem, the quantifiable 
health benefits for patients, clinicians, commissioners and the health system 
itself, how the implementation of this product will take place, and the 
anticipated revenue generation.  
 
E-therapy developers will need to carefully consider the stage in development 
in which dissemination will occur. The time required to achieve the ‘gold 
standard’ of evidence from a randomised controlled trial (RCT) contrasts with 
the fast pace of technological advancements and demand for online access to 
psychological treatments.  Furthermore, for industry, there is limited 
commercial appeal in waiting years before seeing a return of an investment 
(particularly if it risks the product going out of date or being pre-empted by a 
competitor). However, this should not be seen as justification for widespread 
NHS uptake of products that do not have an evidence-base. Instead 
developers and funders need to carefully consider ways to evaluate new 
products efficiently. For example, it may be more efficient to use online 
technologies to assess and recruit potential participants to an RCT and to 
evaluate outcomes than to use a face-to-face approach (although this will not 
be appropriate in all circumstances).  There are also a range of study designs, 
other than the RCT (32), that may prove useful in evaluating novel e-
therapies. Healthcare providers can usefully inform decision making about 
what constitutes appropriate evaluation, by clearly specifying the level of 
evidence that should be required to justify commissioning and insisting that 
this is met.  
 
Going Forward 
As the appetite for and provision of e-therapies grows, there is a pressing 
need for key stakeholders (e.g. researchers, clinicians, industry, healthcare 
providers, service users) to join together to consider the issues raised here, 
and to share information, expertise and experience, and to develop 
collaborations.  Indeed technology, such as virtual conferences and online 
“dating”, can be used to facilitate these interactions.  Technological advances 
such as wearable technology, artificial intelligence, and virtual reality also 
open up a wealth of clinical possibilities.  For example, emerging evidence 
suggests combining experiential virtual scenarios with real-time monitoring 
using virtual reality and wearable biosensors can reduce anxiety among 
teachers and nurses (33). 
 
So far these issues have received limited attention in the academic and 
clinical literature, although the field has started to utilise key conferences such 
as the International Society for Research on Internet Interventions (ISRII) as a 
platform for debate.  In navigating the challenges of digital mental health 
development and dissemination, key stakeholders in the UK could seize the 
opportunity to learn from the lessons of our international colleagues who have 
been quick to develop and evaluate online interventions, but are now often 
struggling to disseminate these into routine clinical practice.  Unfortunately, 
there is still a tendency for clinical academics to focus on the development 
and evaluation rather than considering how these innovations can be 
embedded within usual care pathways and ultimately adopted by healthcare 
providers and their service users. 
 
 
Recommendations 
Based on our analysis of the current issues in the field, we would recommend 
that clinicians and academics developing online psychological interventions: 
 Carefully consider and plan at the start of their project how to scale up 
and sustain the online intervention beyond the duration of the grant 
funding. 
 Develop and commercialise the online intervention collaboratively with 
industry partners who have the expertise to supply digital health 
products to healthcare providers. 
 Develop a business plan for the commercialisation and ensure that 
health economic analysis is incorporated in research studies. 
 Consider up front which parties own which aspects of the Intellectual 
Property and that this fits with the funding body and organisational 
stipulations. 
 Involve service users and other intended end-users in the design. 
 Work collaboratively with the targeted clinical services to ensure that 
the online solution meets the needs of the service and can be 
embedded within their care pathways. 
 Explore alternative study designs to the RCT that are efficient and 
provide ongoing evidence for the digital mental health innovation. 
 Link up with external agencies such as the UK’s AHSN for advice and 
guidance on commercialisation and adoption by healthcare providers.    
 
We would also argue that there is a pressing need for a dialogue between the 
key stakeholders and relevant funding bodies in order to raise awareness of 
the issues highlighted above, and the need to work innovatively to enable 
successful collaborations with industry that facilitate the adoption of digital 
mental health innovations by healthcare providers. Furthermore, the UK 
government should consider applying the approach taken in other countries 
such as Australia and, more recently, Sweden, in commissioning a national 
online psychological treatment service.  This approach has the potential to 
ensure that online treatments are developed in a standard, secure platform, 
have a clear and immediate route to wide-scale dissemination, are delivered 
by appropriately trained and supervised clinicians with particular expertise in 
delivering online interventions, and provide an unparalled opportunity for 
ongoing research and development.  
 
Conclusion 
The digital era is undeniably exciting, however careful planning is required to 
ensure that e-therapies demonstrate clinical efficacy, cost effectiveness, 
acceptability and, crucially, are adopted by healthcare providers and 
embedded with routine clinical practice to ensure they are available as a 
treatment option for service users.  
   
Currently digital mental health innovation is expanding beyond the pace of 
scientific evaluation and it is clear that clinical and research communities need 
to catch up. Various options for development and routes for dissemination 
have been presented, alongside their challenges. Whilst the specifics may 
become obsolete as e-therapies evolve, we hope that the guiding principles 
behind our recommendations will remain a useful framework to ensure that 
the digital era of healthcare is evidence based, loyal to scientific rigour and is 
informed by and responsive to the needs of services and service users. 
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